Total debt rose from $13.2B to $34.0B before easing to $31.2B, pushing debt-to-equity from 0.25 to 0.65 and then to 0.60, while cash fell from $8.5B at year-end 2025 to $4.1B, indicating a sharp event-driven leverage shift that has thinned the liquidity buffer.
Abbott Laboratories (ABT) balance sheet — 30-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Total Current Assets | 23.5B | 26B | 23.66B | 22.67B | 25.22B | 24.24B | 20.44B | 15.67B | 14.63B | 20.15B | 26.78B | 14.15B | 15.26B | 19.25B | 31.32B | 23.77B | 22.32B | 23.31B | 17.04B | 14.04B | 11.28B | 11.39B | 10.73B | 10.29B | 9.12B | 8.42B | 7.38B | 6.42B | 5.55B | 5.04B | 4.48B |
| Cash & Short-Term Investments | 4.3B | 8.94B | 7.97B | 7.28B | 10.17B | 10.25B | 7.15B | 4.14B | 4.09B | 9.61B | 18.77B | 6.13B | 4.46B | 8.1B | 15.17B | 8.1B | 7.32B | 9.93B | 5.08B | 2.82B | 1.37B | 2.96B | 2.06B | 1.29B | 966.13M | 713.54M | 1.16B | 723.3M | 383.32M | 259.01M | 123.08M |
| Cash Only | 4.05B | 8.52B | 7.62B | 6.9B | 9.88B | 9.8B | 6.84B | 3.86B | 3.84B | 9.41B | 18.62B | 5B | 4.06B | 3.48B | 10.8B | 6.81B | 7.32B | 8.81B | 4.11B | 2.46B | 521.19M | 2.89B | 2.06B | 995.12M | 704.45M | 657.38M | 914.22M | 608.1M | 308.23M | 230.02M | 110.21M |
| Short-Term Investments | 246M | 417M | 351M | 383M | 288M | 450M | 310M | 280M | 242M | 203M | 155M | 1.12B | 397M | 4.62B | 4.37B | 1.28B | 0 | 1.12B | 967.6M | 364.44M | 852.24M | 62.41M | 0 | 291.3M | 261.68M | 56.16M | 242.5M | 115.2M | 75.09M | 28.99M | 12.88M |
| Accounts Receivable | 9.03B | 7.93B | 6.92B | 6.57B | 6.22B | 6.49B | 6.41B | 5.42B | 5.18B | 5.25B | 3.25B | 3.42B | 3.59B | 3.99B | 7.61B | 7.68B | 7.18B | 6.54B | 5.47B | 4.95B | 4.23B | 3.58B | 3.7B | 3.31B | 2.93B | 2.81B | 2.18B | 2.06B | 1.96B | 1.78B | 1.71B |
| Days Sales Outstanding | 63.89 | 65.29 | 60.25 | 59.74 | 51.99 | 54.97 | 67.65 | 62.07 | 61.86 | 69.95 | 56.85 | 61.14 | 64.65 | 66.59 | 69.69 | 72.19 | 74.56 | 77.61 | 67.56 | 69.68 | 68.71 | 58.44 | 68.55 | 61.45 | 60.42 | 63.04 | 57.87 | 56.94 | 57.21 | 54.74 | 56.63 |
| Inventory | 7.34B | 6.49B | 6.19B | 6.57B | 6.17B | 5.16B | 5.01B | 4.32B | 3.8B | 3.6B | 2.43B | 2.6B | 2.64B | 2.69B | 3.79B | 3.28B | 3.19B | 3.26B | 2.78B | 2.95B | 2.81B | 2.54B | 2.62B | 2.74B | 2.44B | 2.21B | 1.74B | 1.5B | 1.41B | 1.28B | 1.24B |
| Days Inventory Outstanding | 123.88 | 120.08 | 109.61 | 119.47 | 105.63 | 94.77 | 106.17 | 103.57 | 93.9 | 91.76 | 92.46 | 100.44 | 98.87 | 100.3 | 130.12 | 77.79 | 79.86 | 90.65 | 81.17 | 95.1 | 106.32 | 88.64 | 107.66 | 105.51 | 104.76 | 104.2 | 101.88 | 91.32 | 95.44 | 92.59 | 95.51 |
| Other Current Assets | 2.83B | 2.64B | 2.57B | 2.26B | 2.66B | 2.35B | 1.87B | 1.79B | 1.57B | 1.69B | 2.32B | 2.01B | 2.87B | 4.47B | 4.74B | 4.7B | 4.62B | 3.58B | 3.72B | 3.32B | 2.87B | 2.31B | 2.36B | 1.17B | 1.02B | 1.11B | 0 | 0 | 1.05M | 28.93M | 12.89M |
| Total Non-Current Assets | 84.75B | 60.72B | 57.76B | 50.54B | 49.21B | 50.96B | 52.11B | 52.22B | 52.54B | 56.1B | 28.23B | 29.85B | 30.23B | 23.71B | 35.91B | 36.51B | 38.26B | 29.27B | 25.38B | 25.67B | 24.9B | 17.76B | 18.03B | 16.42B | 15.14B | 14.88B | 7.91B | 8.05B | 7.66B | 7.02B | 6.64B |
| Property, Plant & Equipment | 12.88B | 12.94B | 11.73B | 11.28B | 10.28B | 10.11B | 10.13B | 8.97B | 7.56B | 7.61B | 5.71B | 5.73B | 5.93B | 5.91B | 8.06B | 7.87B | 7.97B | 7.62B | 7.22B | 7.52B | 6.95B | 6B | 6.01B | 6.28B | 5.83B | 5.55B | 4.82B | 4.77B | 4.74B | 4.57B | 4.46B |
| Fixed Asset Turnover | 3.78x | 3.43x | 3.58x | 3.56x | 4.25x | 4.26x | 3.42x | 3.56x | 4.04x | 3.60x | 3.66x | 3.56x | 3.41x | 3.70x | 4.95x | 4.93x | 4.41x | 4.04x | 4.09x | 3.45x | 3.24x | 3.72x | 3.28x | 3.13x | 3.03x | 2.93x | 2.85x | 2.76x | 2.63x | 2.60x | 2.47x |
| Goodwill | 32.64B | 24.04B | 23.11B | 23.68B | 22.8B | 23.23B | 23.74B | 23.2B | 23.25B | 24.02B | 7.68B | 9.64B | 10.07B | 9.77B | 15.77B | 15.71B | 15.93B | 13.2B | 9.99B | 10.13B | 9.45B | 5.22B | 5.69B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 19.59B | 5.53B | 6.65B | 8.81B | 10.45B | 12.74B | 14.78B | 17.02B | 18.94B | 21.47B | 4.54B | 5.56B | 6.2B | 5.74B | 8.59B | 9.99B | 12.15B | 6.29B | 5.15B | 5.72B | 6.4B | 4.74B | 5.17B | 8.54B | 7.65B | 7.29B | 1.56B | 1.57B | 1.35B | 1.11B | 979.79M |
| Long-Term Investments | 4.22B | 918M | 886M | 799M | 766M | 903M | 1.03B | 931M | 897M | 883M | 2.95B | 4.04B | 229M | 119M | 274M | 378.23M | 302.05M | 1.13B | 1.07B | 1.13B | 1.23B | 134.01M | 291.49M | 77M | 271.65M | -1.38B | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 18.54B | 17.3B | 15.38B | 5.97B | 4.92B | 3.97B | 2.42B | 2.1B | 1.89B | 2.12B | 3.35B | 492M | 3B | 2.17B | 3.21B | 2.56B | 1.9B | 1.02B | 1.95B | 1.18B | 867.08M | 1.66B | 876.93M | 329.36M | -20.87M | 2.03B | 1.53B | 1.71B | 1.57B | 1.34B | 1.2B |
| Total Assets | 108.25B | 86.71B | 81.41B | 73.21B | 74.44B | 75.2B | 72.55B | 67.89B | 67.17B | 76.25B | 55.01B | 44B | 43.79B | 42.95B | 67.23B | 60.28B | 60.57B | 52.58B | 42.42B | 39.71B | 36.18B | 29.14B | 28.77B | 26.72B | 24.26B | 23.3B | 15.28B | 14.47B | 13.22B | 12.06B | 11.13B |
| Asset Turnover | 0.47x | 0.51x | 0.52x | 0.55x | 0.59x | 0.57x | 0.48x | 0.47x | 0.46x | 0.36x | 0.38x | 0.46x | 0.46x | 0.51x | 0.59x | 0.64x | 0.58x | 0.59x | 0.70x | 0.65x | 0.62x | 0.77x | 0.68x | 0.74x | 0.73x | 0.70x | 0.90x | 0.91x | 0.94x | 0.99x | 0.99x |
| Asset Growth % | 100.7% | 6.51% | 11.2% | -1.64% | -1.01% | 3.65% | 6.87% | 1.06% | -11.9% | 38.61% | 25.02% | 0.48% | 1.95% | -36.12% | 11.54% | -0.49% | 15.2% | 23.96% | 6.81% | 9.77% | 24.15% | 1.3% | 7.68% | 10.13% | 4.13% | 52.43% | 5.61% | 9.49% | 9.58% | 8.41% | 18.2% |
| Total Current Liabilities | 16.15B | 16.5B | 14.16B | 13.84B | 15.49B | 13.11B | 11.91B | 10.86B | 9.01B | 8.91B | 6.66B | 9.19B | 10.53B | 9.51B | 13.28B | 15.48B | 17.26B | 13.05B | 11.59B | 9.1B | 11.95B | 7.42B | 6.83B | 7.64B | 7B | 7.93B | 4.3B | 4.52B | 4.96B | 5.03B | 4.34B |
| Accounts Payable | 4.66B | 4.24B | 4.2B | 4.29B | 4.61B | 4.41B | 3.95B | 3.25B | 2.98B | 2.4B | 1.18B | 1.08B | 1.06B | 1.03B | 1.8B | 1.72B | 1.54B | 1.28B | 1.35B | 1.22B | 1.18B | 1.03B | 1.05B | 1.08B | 1.66B | 1.53B | 1.36B | 1.23B | 1.06B | 1B | 923M |
| Days Payables Outstanding | 80.9 | 78.47 | 74.24 | 78.1 | 78.84 | 81.01 | 83.59 | 78.03 | 73.59 | 61.21 | 44.75 | 41.77 | 39.8 | 38.21 | 61.65 | 40.76 | 38.46 | 35.56 | 39.52 | 39.29 | 44.54 | 36.01 | 43.32 | 41.55 | 71.3 | 71.85 | 79.33 | 74.92 | 71.55 | 72.42 | 71.2 |
| Short-Term Debt | 1.71B | 3.31B | 1.75B | 1.32B | 2.48B | 999M | 461M | 1.68B | 207M | 714M | 1.32B | 3.13B | 4.44B | 3.17B | 2.39B | 3.37B | 6.39B | 5.19B | 2.73B | 2.73B | 5.4B | 2.06B | 1.99B | 2.54B | 2.15B | 2.95B | 479.45M | 896.27M | 1.76B | 1.78B | 1.38B |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.18B | 2.2B | 2.29B | 1.55B | 1.43B | 1.38B | 1.41B | 1.21B |
| Other Current Liabilities | 7.89B | 5.54B | 5.91B | 6.13B | 6.5B | 5.77B | 5.72B | 4.46B | 4.34B | 4.3B | 3.22B | 3.8B | 3.92B | 4.23B | 7.01B | 8.61B | 6.7B | 5.02B | 5.69B | 4.22B | 4.3B | 3.21B | 2.98B | 1.84B | 989.42M | 1.16B | 912.86M | 960.16M | 766.94M | 845.88M | 830.44M |
| Current Ratio | 1.45x | 1.58x | 1.67x | 1.64x | 1.63x | 1.85x | 1.72x | 1.44x | 1.62x | 2.26x | 4.02x | 1.54x | 1.45x | 2.02x | 2.36x | 1.54x | 1.29x | 1.79x | 1.47x | 1.54x | 0.94x | 1.54x | 1.57x | 1.35x | 1.30x | 1.06x | 1.72x | 1.42x | 1.12x | 1.00x | 1.03x |
| Quick Ratio | 1.00x | 1.18x | 1.23x | 1.16x | 1.23x | 1.46x | 1.30x | 1.04x | 1.20x | 1.86x | 3.65x | 1.26x | 1.20x | 1.74x | 2.07x | 1.32x | 1.11x | 1.54x | 1.23x | 1.22x | 0.71x | 1.19x | 1.19x | 0.99x | 0.95x | 0.78x | 1.31x | 1.09x | 0.83x | 0.75x | 0.75x |
| Cash Conversion Cycle | 106.88 | 106.89 | 95.63 | 101.11 | 78.79 | 68.73 | 90.23 | 87.6 | 82.17 | 100.5 | 104.56 | 119.8 | 123.72 | 128.68 | 138.16 | 109.21 | 115.96 | 132.71 | 109.21 | 125.48 | 130.5 | 111.08 | 132.89 | 125.41 | 93.87 | 95.4 | 80.42 | 73.35 | 81.11 | 74.91 | 80.94 |
| Total Non-Current Liabilities | 40.47B | 17.45B | 19.36B | 20.55B | 22.04B | 26.07B | 27.64B | 25.72B | 27.44B | 36.24B | 27.63B | 13.49B | 11.69B | 8.18B | 27.14B | 20.27B | 20.55B | 16.34B | 13.35B | 12.83B | 10.17B | 7.31B | 7.62B | 6B | 6.59B | 6.31B | 2.41B | 2.53B | 2.54B | 2.03B | 1.96B |
| Long-Term Debt | 29.45B | 10.83B | 12.63B | 13.6B | 14.52B | 17.3B | 18.53B | 16.66B | 19.36B | 27.21B | 20.68B | 5.87B | 3.39B | 3.39B | 18.09B | 12.04B | 12.52B | 11.27B | 8.71B | 9.49B | 7.01B | 4.57B | 4.79B | 3.45B | 4.27B | 4.34B | 1.08B | 1.34B | 1.34B | 937.98M | 932.9M |
| Capital Lease Obligations | 931M | 931M | 896M | 949M | 943M | 956M | 902M | 755M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 1.96B | 1.96B | 1.37B | 1.22B | 1.84B | 2.07B | 2.15B | 2.13B | 2.06B | 2.01B | 2.7B | 3.56B | 3.46B | 466M | 710M | 703M | 1.11B | 165M | 0 | 0 | 0 | 583.08M | 220.08M | 0 | 0 | 0 | 0 | 23.78M | 108.96M | 136.51M | 153.28M |
| Other Non-Current Liabilities | 11.02B | 3.73B | 4.46B | 4.78B | 4.74B | 5.74B | 6.06B | 6.18B | 6.02B | 7.02B | 4.25B | 4.06B | 4.84B | 4.33B | 8.35B | 7.53B | 6.91B | 4.91B | 4.63B | 3.34B | 3.16B | 2.16B | 2.61B | 2.55B | 2.32B | 1.97B | 1.34B | 1.17B | 1.09B | 953.43M | 875.52M |
| Total Liabilities | 56.62B | 33.94B | 33.51B | 34.39B | 37.53B | 39.17B | 39.55B | 36.59B | 36.45B | 45.15B | 31.95B | 19.92B | 19.64B | 17.69B | 40.42B | 35.75B | 36.99B | 29.52B | 24.94B | 21.94B | 22.12B | 14.73B | 14.44B | 13.64B | 13.59B | 14.24B | 6.71B | 7.04B | 7.5B | 7.06B | 6.31B |
| Total Debt | 31.16B | 15.07B | 15.28B | 15.87B | 17.95B | 19.25B | 19.89B | 19.1B | 19.57B | 27.92B | 22.01B | 9B | 7.83B | 6.56B | 20.48B | 15.41B | 18.92B | 16.46B | 11.45B | 12.21B | 12.41B | 6.63B | 6.78B | 5.99B | 6.42B | 7.29B | 1.56B | 2.23B | 3.1B | 2.72B | 2.32B |
| Net Debt | 27.11B | 6.54B | 7.66B | 8.98B | 8.06B | 9.45B | 13.05B | 15.24B | 15.72B | 18.52B | 3.39B | 4B | 3.77B | 3.09B | 9.67B | 8.6B | 11.59B | 7.65B | 7.33B | 9.76B | 11.89B | 3.74B | 4.72B | 4.99B | 5.72B | 6.63B | 641.6M | 1.62B | 2.79B | 2.49B | 2.21B |
| Debt / Equity | 0.60x | 0.29x | 0.32x | 0.41x | 0.49x | 0.53x | 0.60x | 0.61x | 0.64x | 0.90x | 1.06x | 0.42x | 0.36x | 0.26x | 0.76x | 0.63x | 0.83x | 0.71x | 0.65x | 0.69x | 0.88x | 0.46x | 0.47x | 0.46x | 0.60x | 0.80x | 0.18x | 0.30x | 0.54x | 0.54x | 0.48x |
| Debt / EBITDA | 2.83x | 1.35x | 1.52x | 1.64x | 1.54x | 1.51x | 2.31x | 2.51x | 2.75x | 5.59x | 4.78x | 2.04x | 1.78x | 1.79x | 4.27x | 1.56x | 1.96x | 1.90x | 1.44x | 1.80x | 2.11x | 1.10x | 1.24x | 1.46x | 1.53x | 2.38x | 0.37x | 0.56x | 0.79x | 0.76x | 0.70x |
| Net Debt / EBITDA | 2.46x | 0.59x | 0.76x | 0.93x | 0.69x | 0.74x | 1.51x | 2.00x | 2.21x | 3.71x | 0.74x | 0.90x | 0.86x | 0.84x | 2.02x | 0.87x | 1.20x | 0.88x | 0.92x | 1.43x | 2.02x | 0.62x | 0.86x | 1.22x | 1.36x | 2.17x | 0.15x | 0.41x | 0.72x | 0.70x | 0.67x |
| Interest Coverage | 7.72x | 25.83x | 12.63x | 10.55x | 27.37x | 21.03x | 8.02x | 5.98x | 4.94x | 3.54x | 5.65x | 18.88x | 16.35x | 44.43x | 1.75x | 6.11x | 8.13x | 35.15x | 12.08x | 8.54x | 6.47x | 20.14x | 21.61x | 21.04x | 15.88x | 0.01x | 146.44x | - | - | - | - |
| Total Equity | 51.62B | 52.77B | 47.9B | 38.83B | 36.91B | 36.02B | 33B | 31.3B | 30.72B | 31.1B | 20.72B | 21.33B | 21.64B | 25.27B | 26.81B | 24.53B | 22.77B | 23.19B | 17.48B | 17.78B | 14.05B | 14.42B | 14.33B | 13.07B | 10.66B | 9.06B | 8.57B | 7.43B | 5.71B | 5B | 4.82B |
| Equity Growth % | 20.12% | 10.17% | 23.37% | 5.21% | 2.45% | 9.15% | 5.44% | 1.88% | -1.21% | 50.11% | -2.86% | -1.45% | -14.36% | -5.77% | 9.32% | 7.74% | -1.82% | 32.65% | -1.68% | 26.5% | -2.5% | 0.62% | 9.59% | 22.58% | 17.72% | 5.7% | 15.39% | 30% | 14.3% | 3.7% | 9.63% |
| Book Value per Share | 29.70 | 30.21 | 27.40 | 22.20 | 20.92 | 20.14 | 18.48 | 17.57 | 17.36 | 17.78 | 13.97 | 14.16 | 14.17 | 16.05 | 16.84 | 15.62 | 14.63 | 14.91 | 11.20 | 11.40 | 9.15 | 9.22 | 9.12 | 8.32 | 6.78 | 5.78 | 5.47 | 4.77 | 3.66 | 3.17 | 3.05 |
| Total Shareholders' Equity | 51.03B | 52.13B | 47.66B | 38.6B | 36.69B | 35.8B | 32.78B | 31.09B | 30.52B | 30.9B | 20.54B | 21.21B | 21.53B | 25.17B | 26.72B | 24.44B | 22.68B | 23.14B | 17.48B | 17.78B | 14.05B | 14.42B | 14.33B | 13.07B | 10.66B | 9.06B | 8.57B | 7.43B | 5.71B | 5B | 4.82B |
| Common Stock | 25.64B | 25.53B | 25.15B | 24.87B | 24.71B | 24.47B | 24.14B | 23.85B | 23.51B | 23.21B | 13.03B | 12.73B | 12.38B | 12.05B | 11.76B | 9.82B | 8.74B | 8.26B | 7.44B | 6.1B | 4.29B | 3.52B | 3.24B | 3.03B | 2.89B | 2.64B | 2.22B | 1.94B | 1.23B | 907.11M | 694.38M |
| Retained Earnings | 49.64B | 49.78B | 47.26B | 37.55B | 35.26B | 31.53B | 27.63B | 25.85B | 24.56B | 23.98B | 25.57B | 25.76B | 22.87B | 21.98B | 24.15B | 20.91B | 18.93B | 17.05B | 13.83B | 10.81B | 9.57B | 10.4B | 10.03B | 9.69B | 8.6B | 7.28B | 7.23B | 6.17B | 4.55B | 4.43B | 4.26B |
| Treasury Stock | -17.91B | -17.18B | -16.84B | -15.98B | -15.23B | -11.82B | -10.04B | -10.15B | -9.96B | -10.22B | -10.79B | -10.62B | -8.68B | -6.84B | -5.59B | -3.69B | -3.92B | -3.31B | -2.63B | -1.21B | -195.24M | -212.25M | -220.85M | -229.7M | -231.84M | -252.44M | -255.59M | -257.76M | -46.7M | -48.24M | -50.6M |
| Accumulated OCI | -6.34B | -6B | -7.91B | -7.84B | -8.05B | -8.37B | -8.95B | -8.46B | -7.59B | -6.06B | -7.26B | -6.66B | -5.05B | -2.01B | -3.59B | -2.6B | -1.37B | 854.07M | -1.16B | 2.08B | 389.77M | 699.19M | 1.27B | 576.42M | -596.25M | -612.97M | -621.33M | -428.33M | -25.33M | -288.19M | -86.4M |
| Minority Interest | 596M | 641M | 237M | 224M | 219M | 222M | 219M | 213M | 198M | 201M | 179M | 115M | 113M | 96M | 92.27M | 86.31M | 88.33M | 43.1M | 39.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ABT stock.
As of 2025, Abbott Laboratories (ABT) had total assets of $86.71B including $26.00B in current assets.
Abbott Laboratories (ABT) carries total debt of $15.07B, offset by $8.94B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Abbott Laboratories (ABT) has total shareholders' equity (book value) of $52.13B ($30.21 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Abbott Laboratories (ABT) reported a current ratio of 1.58x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Legal exposure and leverage volatility
Metrics are mathematically derived from official filings.
Leverage Swings Mask Underlying Stability
Based on reported quarterly balance sheets, ABT's total debt rose from $13.2B to $34.0B and then fell to $31.2B, while its debt-to-equity ratio moved from 0.25 to 0.65 before retreating to 0.60, pointing to a sharp, event-driven shift in capital structure rather than a gradual trend.
The jump in total assets and goodwill from roughly $24B to $35B alongside rising debt suggests an acquisition-led expansion funded partly by borrowing. Retained earnings have stayed close to $50B, which indicates the equity base has been stable rather than eroded, so the leverage spike appears more like a financing choice than a sign of operating stress. Investors should monitor whether debt continues to decline as the reported figures imply.
Debt Reduction Eases Refinancing Pressure
According to the reported filings, ABT reduced total debt from $34.0B in Q1 2026 to $31.2B in Q3 2026, bringing debt-to-equity down to 0.60, a reduction that lowers near-term refinancing exposure but still leaves leverage well above the 2025 levels.
Debt-to-equity of 0.60 remains moderate relative to MDT at 0.56 and BSX at 0.51, while BAX at 1.64 shows the sector includes far more levered balance sheets. The pace of repayment implies management is prioritizing deleveraging, which may suggest the 2026 borrowing was tied to a discrete transaction. Whether the remaining debt load is sustainable depends on free cash flow holding up through quarters where working capital has been volatile.
Cash Buffer Thins as Debt Is Repaid
Based on ABT's reported figures, cash fell from $8.5B at year-end 2025 to $4.1B in Q3 2026 while the current ratio eased from 1.58 to 1.45, indicating that liquidity has been drawn down as debt was retired.
A current ratio near 1.45 remains adequate for a company of this scale, but the sharp cash decline reduces the buffer available against operating shocks such as product recalls or litigation settlements. The reported figures suggest the company has been using cash to service obligations rather than building reserves. Investors should watch whether cash rebuilds in coming quarters or whether reliance on operating cash flow increases.
Goodwill Expansion Raises Impairment Exposure
As reported in the balance sheets, ABT's goodwill climbed from $23.4B to $35.2B during 2026 before easing to $32.6B, representing a large share of total assets that now sits near $108B and warrants close attention to future impairment risk.
Goodwill now accounts for roughly 30% of total assets, which increases sensitivity to any deterioration in the earnings of acquired businesses such as the diagnostics and nutrition units. Net PPE of about $12.9B is comparatively modest, indicating an asset base weighted toward intangibles rather than physical capacity. The reported figures suggest that the quality of the asset base depends heavily on whether acquired franchises continue to generate returns that justify their carrying values.
Deferred Revenue Absence Limits Visibility
Based on the reported balance sheets, ABT carries no disclosed deferred revenue in any of the ten quarters, which removes a conventional forward indicator and means the headline balance sheet offers little direct evidence about future contracted demand.
The absence of deferred revenue is not itself evidence of weakness, but it limits the ability to read forward demand from the balance sheet alone, particularly for the consumable diagnostics and sensor businesses. Combined with a 32% concentration of tracked risk factors in legal and regulatory matters, this gap suggests analysts should rely more on segment disclosures than balance sheet signals. The data available does not allow firm conclusions about backlog or unearned obligations.